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Abstract
Aims/hypothesis Current genetic tests for diagnosing mono-
genic diabetes rely on selection of the appropriate gene for
analysis according to the patient’s phenotype. Next-
generation sequencing enables the simultaneous analysis
of multiple genes in a single test. Our aim was to develop a
targeted next-generation sequencing assay to detect muta-
tions in all known MODY and neonatal diabetes genes.
Methods We selected 29 genes in which mutations have
been reported to cause neonatal diabetes, MODY, mater-
nally inherited diabetes and deafness (MIDD) or familial
partial lipodystrophy (FPLD). An exon-capture assay was
designed to include coding regions and splice sites. A total
of 114 patient samples were tested—32 with known
mutations and 82 previously tested for MODY (n=33) or
neonatal diabetes (n=49) but in whom a mutation had not
been found. Sequence data were analysed for the presence
of base substitutions, small insertions or deletions (indels)
and exonic deletions or duplications.
Results In the 32 positive controls we detected all
previously identified variants (34 mutations and 36 poly-
morphisms), including 55 base substitutions, ten small
insertions or deletions and five partial/whole gene
deletions/duplications. Previously unidentified mutations
were found in five patients with MODY (15%) and nine
with neonatal diabetes (18%). Most of these patients (12/14)
had mutations in genes that had not previously been tested.
Conclusions/interpretation Our novel targeted next-
generation sequencing assay provides a highly sensitive
method for simultaneous analysis of all monogenic diabetes
genes. This single test can detect mutations previously
identified by Sanger sequencing or multiplex ligation-
dependent probe amplification dosage analysis. The increased
number of genes tested led to a higher mutation detection rate.
Keywords Geneticdiagnosis .MIDD .MODY .Monogenic
diabetes . Neonatal diabetes . Next-generation sequencing
Abbreviations
FPLD Familial partial lipodystrophy
MIDD Maternally inherited diabetes and deafness
MLPA Multiplex ligation-dependent probe amplification
TRMA Thiamine-responsive megaloblastic anaemia
Introduction
A genetic diagnosis of monogenic diabetes enables some
patients to stop insulin treatment. Patients with MODY
caused by mutations in the transcription factor genes
HNF1A and HNF4A are sensitive to low-dose sulfonylureas
[1] and those with GCK mutations do not require
pharmacological treatment. Most patients with neonatal
diabetes caused by mutations in the KCNJ11 or ABCC8
genes encoding the K-ATP channel subunits Kir6.2 or
SUR1 achieve improved glycaemic control with high-dose
sulfonylureas [2].
Current diagnostic testing uses Sanger sequencing as the
gold standard to detect base substitutions and small indels
(insertions or deletions). An additional assay, often
multiplex ligation-dependent probe amplification (MLPA),
is required for the identification of partial/whole gene
deletions or duplications [3]. Genetic testing is usually
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restricted to a small subset of genes according to the
patient’s phenotype [4].
Next-generation sequencing technology provides the
potential for simultaneous analysis of all the known disease
genes in a single assay at a similar cost to testing a few
genes by Sanger sequencing. Targeted assays for gene
panels ranging from two to 105 genes have been developed
for polycystic kidney disease [5], Bardet–Biedl/Alström
syndrome [6] and retinal disease [7]. We developed a
targeted next-generation sequencing assay to identify
mutations causing monogenic diabetes and tested it in a
cohort of patients in whom previous testing for MODY or
neonatal diabetes had failed to confirm a genetic diagnosis.
Methods
We designed a custom Agilent SureSelect exon-capture
assay (Agilent Technologies, Santa Clara, CA, USA) with
baits for 29 genes (see electronic supplementary material
[ESM] Methods). These included 13 known/putative
MODY genes (GCK, HNF1A, HNF4A, HNF1B,
NEUROD1, INS, CEL, PDX1, PAX4, BLK, KLF11, KCNJ11
and ABCC8), two genes where mutations cause diabetes
through lipodystrophy (LMNA and PPARG), the m.3243
region of the mitochondrial genome (where the
m.3243A>G mutation causes MIDD) and 20 neonatal
diabetes genes (GCK, KCNJ11, ABCC8, INS, PDX1,
PTF1A, HNF1B, NEUROD1, NEUROG3, RFX6, EIF2AK3,
FOXP3, GLIS3, SLC19A2, SLC2A2, IER3IP1, ZFP57,
WFS1, GATA6 and GATA4). Bait density and replication
were adjusted using coverage data from exome sequencing
samples, captured with the Agilent SureSelect Human All
Exon v1 (38 Mb) system (see ESM Fig. 1), to achieve
greater uniformity of capture across the 66.8 kb target.
DNA samples from a total of 114 patients were
tested—32 with known mutations identified by Sanger
sequencing, MLPA dosage or array CGH (comparative
genomic hybridisation) and 82 previously tested for MODY
(n=33, diagnosed at age <35 years, BMI <30 kg/m2, who
had undergone previous testing for GCK, HNF1A and/or
HNF4A) or neonatal diabetes diagnosed before 6 months
(n=49, all previously tested for mutations in at least
KCNJ11, ABCC8 and INS) but in whom a mutation had not
been found. Study participants gave informed consent and
these investigations were carried out in accordance with the
Declaration of Helsinki as revised in 2000.
Samples were fragmented using a Bioruptor (Diagenode,
Liège, Belgium), indexed for multiplexing and hybridised
(in pools of 12 samples) according to the manufacturer’s
instructions. Sequencing was performed with an Illumina
HiSeq 2000 (Illumina, San Diego, CA, USA) (48 samples
per lane) and 100 bp paired end reads. Data were processed
as described previously [8] to identify potential pathogenic
mutations located within 50 bp upstream and 10 bp
downstream of each exon. Deletions/duplications >30 bp
were identified by relative read depth coverage. All newly
identified mutations were confirmed by Sanger sequencing.
Results
The targeted next-generation sequencing assay ‘captured’ the
protein coding regions and conserved splice sites of the 28
monogenic diabetes genes and the m.3243 region of the
mitochondrial genome from the patients’ DNA samples by
hybridisation. These DNA fragments were then amplified and
sequenced on an Illumina HiSeq 2000 to generate multiple
reads per base. The average read depth across the targeted gene
regions in the 114 samples was 257 per base (SD ±85) with ≥30
reads for 97.5% of bases and ≥20 reads for 98.0% of bases. For
the 20 genes where testing is currently available in our
laboratory by Sanger sequencing, the average depth of coverage
was 272 and 99.4% of bases had a minimum read depth of 30
(Fig. 1a). One specific region of low coverage was observed
across a ∼300 bp GC-rich region of GATA6 exon 2 (Fig. 1b).
We identified all 34 mutations in the 32 positive control
samples (Table 1). These included 19 base substitutions, ten
a
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Fig. 1 Depth of coverage for targeted genes. (a) The percentage of
targeted bases sequenced at a minimum depth of 2, 10, 20 and 30 reads
per base for regions of interest for all 28 MODY/neonatal diabetes
genes and the m.3243 base (black bars) and for the 20 genes routinely
tested by Sanger sequencing in our laboratory (white bars). Data are
mean values for the cohort of 114 samples; error bars show 1 SD from
the mean. (b) Region of low coverage (<30 reads per base) within
GATA6 exon 2. The graph shows the average depth of coverage (black
line) in the region chr18:19,751,740–19,752,040 (hg19 coordinates);
grey shading indicates 1 SD from the mean. Average coverage depth
over the entire GATA6 exon 2 region of interest (chr18:19,751,056–
19,752,250) was 126
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small insertions or deletions (≤27 bases) and five partial/whole
gene deletions/duplications (see ESM Fig. 2). The mosaic
GATA6 c.1303-1G>T mutation was present in 142/598 reads
(24%). In these samples a total of 36 different polymorphisms
previously identified by Sanger sequencing were confirmed.
There were no false-positive variant calls. The sensitivity and
specificity for variant identification was 100% (Clopper–
Pearson 95% CI 94.9, 100).
Previously unidentified mutations were found in 5/33
patients (15%) referred for MODY testing (Table 1). A
mitochondrial m.3243A>G mutation was found in two
patients in whom HNF1A testing had been requested and
confirmed a diagnosis of MIDD. Mutations were identified
in the GCK, HNF1B and HNF4A genes in three patients
who had previously been tested for HNF1A and HNF4A.
The intronic HNF4A mutation, located five bases from the
exon (c.358+5G>A), was not detected by genetic testing in
1999 because analysis was restricted to the exons and
conserved splice sites (±2 bp). This mutation is predicted to
reduce the splicing efficiency of the intron 3 splice donor
site and was detected in four additional diabetic relatives.
Mutations were found in 9/49 patients (18%) with
neonatal diabetes (Table 1). For eight of these nine patients
the mutated gene had not been analysed previously. In three
cases the mutations were in genes (EIF2AK3 or SLC19A2)
where neonatal diabetes is usually part of a syndrome but
the initial testing was performed soon after the diagnosis of
diabetes, before other features had developed. Novel
mutations were found in GCK, PDX1 and GATA6 in
five patients. The p.R826W ABCC8 mutation had not
been detected previously due to allelic dropout caused
by a polymorphism (rs139233603) within a primer
binding site that was not listed on variant databases at
the time of the Sanger sequencing analysis. This patient
and her affected sibling were compound heterozygotes
for a previously detected inactivating ABCC8 mutation
(c.580-1G>A). Both have now transferred from insulin
to sulfonylurea therapy.
Discussion
This novel targeted next-generation sequencing capture
assay provides a sensitive method for simultaneous testing
of mutations in 29 known/putative monogenic diabetes
genes. The types of mutations identified include base
substitutions, small indels and large deletions/duplications.
A genetic diagnosis was obtained for 14/82 (17%) patients
in whom testing had previously been limited to a subset of
these genes.
Six of the 14 newly identified mutations were in genes
that had not been tested previously because extrapancreatic
features characteristic of the genetic subtype were not
present (e.g. no known renal disease in a patient with an
HNF1B mutation as previously described by Edghill et al
[9]), had not yet presented (e.g. skeletal dysplasia in
Wolcott Rallison syndrome or deafness and megaloblastic
anaemia in TRMA syndrome) or were not noted at referral
for genetic testing (e.g. deafness in MIDD). Two mutations
were in genes where previous testing had yielded a false-
negative result because the mutation was located outside the
region of analysis (HNF4A c.358+5G>A) or was not
detected due to allelic dropout at the PCR stage (ABCC8
p.R826W). For the two siblings with the ABCC8 p.R826W
mutation the test result allowed them to stop their insulin
therapy and replace it with sulfonylurea tablets.
The error rate for next-generation sequencing is
estimated to be 1% [10] and therefore multiple reads are
required to obtain equivalent sensitivity to Sanger sequenc-
ing. We used a bait balancing strategy (increased number of
baits within regions of low coverage predicted from exome
sequencing using the same SureSelect capture system) to
achieve the recommended minimum of 30 reads/base for
clinical diagnostic testing for 99.4% for the 20 genes
currently tested by Sanger sequencing (97.5% bases with
≥30 reads for all 29 genes). Only one GC-rich region of
GATA6 (<0.3 kb out of the total 66.8 kb sequenced) proved
difficult to capture and may require supplementary Sanger
sequencing. The high, even coverage enabled us to detect
all 70 unique mutations or polymorphisms in the positive
controls. Although the assay showed 100% sensitivity and
specificity, validation studies of further variants are required
to reduce the CIs.
Methods for detecting large deletions or duplications
(also known as copy number variants) in targeted next-
generation sequencing data have lagged behind calling
of base substitutions and small indels. Difficulties arise
from the low and variable coverage in many other
targeted assays. Our high, even coverage enabled the
detection of two multi-exonic duplications and three
single or multi-exon deletions by cross-sample
normalisation and comparison. If further studies confirm
the sensitivity of this approach it might be possible to
replace both Sanger sequencing and dosage analysis by
MLPA with a single targeted next-generation sequencing
assay for monogenic diabetes.
Our study suggests that the implementation of targeted
next-generation sequencing for clinical diagnostic testing
will increase the number of patients with confirmed
monogenic diabetes. A genetic diagnosis is important since
it defines the diagnostic subtype, determines the most
appropriate treatment and informs the sibling recurrence
risk or risk of diabetes in offspring. This targeted next-
generation sequencing assay may also prove to be a useful
pre-screen before exome or genome sequencing for disease
gene discovery.
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